Davis Polk advised the joint-bookrunning managers and representatives of the several underwriters in connection with an approximately $173.8 million public offering of common stock by Five Prime Therapeutics, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “FPRX.”
Five Prime is a clinical-stage biotechnology company focused on developing immune modulators and precision therapies to improve the lives of patients with solid tumor cancers. Five Prime’s primary focus is on developing immune-oncology and targeted cancer therapies.
The Davis Polk corporate team included partner Emily Roberts and associates Dongbiao Shen and Joseph G. Marano. Partner David R. Bauer and associate Jay Frankel provided intellectual property advice. Partner Mario J. Verdolini and associate Tomislava Dragicevic provided tax advice. Members of the Davis Polk team are based in the Northern California and New York offices.